Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TB-500 in Adults With Stable Atherosclerotic Cardiovascular Disease
NCT07487363Phase 2Recruiting
- Sponsor
- Hudson Biotech
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of thymosin beta-4 in atherosclerotic cardiovascular disease (ASCVD) and endothelial dysfunction (4 arms), sponsored by Hudson Biotech. Primary endpoints: Incidence of treatment-emergent adverse events at 12 weeks and Incidence of serious adverse events at 28 Days. Started Feb 2026; status: recruiting.
02
Drugs
thymosin beta-4
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)endothelial dysfunction
Beyond the preview
Go deeper on NCT07487363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07487363.